The rise of Viagra initially sparked a surge for pharma, but recent shifts present a uncertain scenario for those considering a stake. Lower-cost versions are eating into profits, and ongoing litigation add further risk to the equation. While some companies could still see gains from adjacent services, the general direction suggests a measured appr